Spyre reported a Q4 2025 net loss of USD 62.53 million, compared with a net loss of USD 56.30 million in Q4 2024. Q4 2025 R&D expenses were USD 44.64 million, while G&A expenses were USD 12.53 million. For FY 2025, Spyre posted a net loss of USD 155.20 million, with R&D expenses of USD 171.65 million and G&A expenses of USD 47.91 million. Spyre ended 2025 with USD 756.5 million in cash, cash equivalents and marketable securities and said this is expected to fund operations into the second half of 2028; net cash used in operating activities was USD 44.6 million in Q4 2025. The company also reported Q4 2025 interest income of USD 7.14 million and total other expense of USD 5.4 million, primarily driven by changes in the fair value of its contingent value right liability. On the business side, Spyre said it remains on track for six proof-of-concept readouts in 2026 across its SKYLINE Phase 2 platform trial in ulcerative colitis and SKYWAY Phase 2 basket trial in rheumatic diseases. SKYLINE Part A induction data are expected to begin in Q2 2026, while SKYWAY sub-studies evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis are expected to deliver proof-of-concept data in Q4 2026. Spyre also highlighted an October 2025 underwritten public offering that raised USD 316.2 million in gross proceeds (before underwriting discounts and offering expenses) and the appointment of Kate Tansey Chevlen as chief commercial officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657114-en) on February 19, 2026, and is solely responsible for the information contained therein.